- Home
- AZ vs NGNE Comparison
AZ vs NGNE Comparison
Compare AZ & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AZ
- NGNE
- Stock Information
- Founded
- AZ 2018
- NGNE 2003
- Country
- AZ Canada
- NGNE United States
- Employees
- AZ N/A
- NGNE N/A
- Industry
- AZ Industrial Machinery/Components
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- AZ Industrials
- NGNE Health Care
- Exchange
- AZ Nasdaq
- NGNE Nasdaq
- Market Cap
- AZ 359.7M
- NGNE 325.3M
- IPO Year
- AZ N/A
- NGNE N/A
- Fundamental
- Price
- AZ $10.45
- NGNE $22.72
- Analyst Decision
- AZ Strong Buy
- NGNE Strong Buy
- Analyst Count
- AZ 1
- NGNE 7
- Target Price
- AZ $20.00
- NGNE $41.86
- AVG Volume (30 Days)
- AZ 282.9K
- NGNE 216.3K
- Earning Date
- AZ 08-13-2025
- NGNE 08-08-2025
- Dividend Yield
- AZ N/A
- NGNE N/A
- EPS Growth
- AZ N/A
- NGNE N/A
- EPS
- AZ N/A
- NGNE N/A
- Revenue
- AZ $7,443,000.00
- NGNE $925,000.00
- Revenue This Year
- AZ $1,343,857.60
- NGNE N/A
- Revenue Next Year
- AZ N/A
- NGNE N/A
- P/E Ratio
- AZ N/A
- NGNE N/A
- Revenue Growth
- AZ N/A
- NGNE N/A
- 52 Week Low
- AZ $1.33
- NGNE $6.88
- 52 Week High
- AZ $12.36
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- AZ 49.15
- NGNE 60.64
- Support Level
- AZ $10.38
- NGNE $20.80
- Resistance Level
- AZ $11.40
- NGNE $23.88
- Average True Range (ATR)
- AZ 0.76
- NGNE 1.44
- MACD
- AZ -0.12
- NGNE 0.09
- Stochastic Oscillator
- AZ 32.98
- NGNE 72.83
About AZ A2Z Smart Technologies Corp.
A2Z Cust2Mate Solutions Corp is engaged in creating shopping carts. With the help of a user-friendly smart algorithm, touch screen, and other technologies, the company streamlines the retail shopping experience by scanning purchased products and enabling in-cart payment so that customers can simply pick & go, and bypass long cashier checkout lines.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.